+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

2019 Future of Mild Cognitive Impairment (MCI) R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

  • PDF Icon

    Report

  • 65 Pages
  • February 2019
  • Region: Global
  • VPA Research
  • ID: 4749286
The global demand for Mild Cognitive Impairment (MCI) treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Mild Cognitive Impairment (MCI) pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Mild Cognitive Impairment (MCI) pipeline companies from advancing their products into Phase 3 or Phase 4.

Mild Cognitive Impairment (MCI) Report Description

The 2019 pipeline study on Mild Cognitive Impairment (MCI) pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Mild Cognitive Impairment (MCI) pipeline compounds.

The Mild Cognitive Impairment (MCI) pipeline guide presents information on all active drugs currently being developed for Mild Cognitive Impairment (MCI). The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Mild Cognitive Impairment (MCI) pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Mild Cognitive Impairment (MCI) drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Mild Cognitive Impairment (MCI) product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Mild Cognitive Impairment (MCI) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

The publisher has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Mild Cognitive Impairment (MCI) pipeline report includes
  • An overview of Mild Cognitive Impairment (MCI) disease including symptoms, causes, diagnosis and available treatment options is provided.

  • Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

  • Phase wise count of Mild Cognitive Impairment (MCI) pipeline

  • Company wise list of Mild Cognitive Impairment (MCI) pipeline

  • Mechanism of Action wise Mild Cognitive Impairment (MCI) pipeline



For each pipeline candidate, the following details are provided:
  • Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)

  • Current status of development

  • Drug overview

  • Mechanism of Action

  • Pre-clinical and Clinical Trials/Results

  • Company Overview and Recent Developments



Reasons to Buy
  • The report is designed to help industry executives promote the success and continued growth of their organizations

  • Get clear understanding of the entire Mild Cognitive Impairment (MCI) pipeline, with details on active projects

  • Stay ahead of the competition through comprehensive knowledge of Mild Cognitive Impairment (MCI) pipeline progress

  • Get in detail information of each product with updated information on each project along with key milestones

  • Gain clear insights into companies participating in Mild Cognitive Impairment (MCI) pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

  • Get trial information for each pipeline product under development

  • Understand the pipeline structure in terms of mechanism of Action, phase and company



The report will be delivered in 2 working days.

Table of Contents

1.1 List of Tables1.2 List of Figures
2. Global Mild Cognitive Impairment (MCI) Pipeline Overview
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology
3. Executive Summary
3.1 Mild Cognitive Impairment (MCI) Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
3.2.1 Pre-clinical
3.2.2 Discovery
3.2.3 Phase 1
3.2.4Phase 2
3.3 Pipeline Drugs in Advanced Stage of Development
3.3.1 Phase 3
3.3.2 Pre-registration
3.4 Companies involved in Mild Cognitive Impairment (MCI) pipeline, H1- 2019
3.5 Mechanism of Action wise Mild Cognitive Impairment (MCI) Pipeline Candidates
4 AbbVie Inc Mild Cognitive Impairment (MCI) Pipeline Details
4.1 AbbVie Inc Business Profile
4.2 AbbVie Inc Mild Cognitive Impairment (MCI) Drug Details
4.3 Drug Snapshot
4.3.1 Originator
4.3.2 Collaborator/Co-Developer
4.3.3 Route of Administration
4.3.4 Orphan Drug/Fast Track/Special Designation
4.3.5 Geography
4.3.6 Type of Molecular Entity
4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments
5 AgeneBio Inc Mild Cognitive Impairment (MCI) Pipeline Details
5.1 AgeneBio Inc Business Profile
5.2 AgeneBio Inc Mild Cognitive Impairment (MCI) Drug Details
5.3 Drug Snapshot
5.3.1 Originator
5.3.2 Collaborator/Co-Developer
5.3.3 Route of Administration
5.3.4 Orphan Drug/Fast Track/Special Designation
5.3.5 Geography
5.3.6 Type of Molecular Entity
5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments
6 Avraham Pharmaceuticals Ltd Mild Cognitive Impairment (MCI) Pipeline Details
6.1 Avraham Pharmaceuticals Ltd Business Profile
6.2 Avraham Pharmaceuticals Ltd Mild Cognitive Impairment (MCI) Drug Details
6.3 Drug Snapshot
6.3.1 Originator
6.3.2 Collaborator/Co-Developer
6.3.3 Route of Administration
6.3.4 Orphan Drug/Fast Track/Special Designation
6.3.5 Geography
6.3.6 Type of Molecular Entity
6.3.7 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments
7 Biogen Inc Mild Cognitive Impairment (MCI) Pipeline Details
7.1 Biogen Inc Business Profile
7.2 Biogen Inc Mild Cognitive Impairment (MCI) Drug Details
7.3 Drug Snapshot
7.3.1 Originator
7.3.2 Collaborator/Co-Developer
7.3.3 Route of Administration
7.3.4 Orphan Drug/Fast Track/Special Designation
7.3.5 Geography
7.3.6 Type of Molecular Entity
7.3.7 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments
8 CereSpir Inc Mild Cognitive Impairment (MCI) Pipeline Details
8.1 CereSpir Inc Business Profile
8.2 CereSpir Inc Mild Cognitive Impairment (MCI) Drug Details
8.3 Drug Snapshot
8.3.1 Originator
8.3.2 Collaborator/Co-Developer
8.3.3 Route of Administration
8.3.4 Orphan Drug/Fast Track/Special Designation
8.3.5 Geography
8.3.6 Type of Molecular Entity
8.3.7 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments
9 Eisai Co Ltd Mild Cognitive Impairment (MCI) Pipeline Details
9.1 Eisai Co Ltd Business Profile
9.2 Eisai Co Ltd Mild Cognitive Impairment (MCI) Drug Details
9.3 Drug Snapshot
9.3.1 Originator
9.3.2 Collaborator/Co-Developer
9.3.3 Route of Administration
9.3.4 Orphan Drug/Fast Track/Special Designation
9.3.5 Geography
9.3.6 Type of Molecular Entity
9.3.7 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments
10 Eli Lilly and Co Mild Cognitive Impairment (MCI) Pipeline Details
10.1 Eli Lilly and Co Business Profile
10.2 Eli Lilly and Co Mild Cognitive Impairment (MCI) Drug Details
10.3 Drug Snapshot
10.3.1 Originator
10.3.2 Collaborator/Co-Developer
10.3.3 Route of Administration
10.3.4 Orphan Drug/Fast Track/Special Designation
10.3.5 Geography
10.3.6 Type of Molecular Entity
10.3.7 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments
11 IntelGenx Corp Mild Cognitive Impairment (MCI) Pipeline Details
11.1 IntelGenx Corp Business Profile
11.2 IntelGenx Corp Mild Cognitive Impairment (MCI) Drug Details
11.3 Drug Snapshot
11.3.1 Originator
11.3.2 Collaborator/Co-Developer
11.3.3 Route of Administration
11.3.4 Orphan Drug/Fast Track/Special Designation
11.3.5 Geography
11.3.6 Type of Molecular Entity
11.3.7 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments
12 Neuron Biopharma SA Mild Cognitive Impairment (MCI) Pipeline Details
12.1 Neuron Biopharma SA Business Profile
12.2 Neuron Biopharma SA Mild Cognitive Impairment (MCI) Drug Details
12.3 Drug Snapshot
12.3.1 Originator
12.3.2 Collaborator/Co-Developer
12.3.3 Route of Administration
12.3.4 Orphan Drug/Fast Track/Special Designation
12.3.5 Geography
12.3.6 Type of Molecular Entity
12.3.7 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments
13 Octapharma AG Mild Cognitive Impairment (MCI) Pipeline Details
13.1 Octapharma AG Business Profile
13.2 Octapharma AG Mild Cognitive Impairment (MCI) Drug Details
13.3 Drug Snapshot
13.3.1 Originator
13.3.2 Collaborator/Co-Developer
13.3.3 Route of Administration
13.3.4 Orphan Drug/Fast Track/Special Designation
13.3.5 Geography
13.3.6 Type of Molecular Entity
13.3.7 Current Status
13.4 Drug Overview
13.5 Drug Mechanism of Action
13.6 Clinical/Pre-clinical Trial Details
13.7 Latest Drug Developments
14 Partner Therapeutics Inc Mild Cognitive Impairment (MCI) Pipeline Details
14.1 Partner Therapeutics Inc Business Profile
14.2 Partner Therapeutics Inc Mild Cognitive Impairment (MCI) Drug Details
14.3 Drug Snapshot
14.3.1 Originator
14.3.2 Collaborator/Co-Developer
14.3.3 Route of Administration
14.3.4 Orphan Drug/Fast Track/Special Designation
14.3.5 Geography
14.3.6 Type of Molecular Entity
14.3.7 Current Status
14.4 Drug Overview
14.5 Drug Mechanism of Action
14.6 Clinical/Pre-clinical Trial Details
14.7 Latest Drug Developments
15 Pfizer Inc Mild Cognitive Impairment (MCI) Pipeline Details
15.1 Pfizer Inc Business Profile
15.2 Pfizer Inc Mild Cognitive Impairment (MCI) Drug Details
15.3 Drug Snapshot
15.3.1 Originator
15.3.2 Collaborator/Co-Developer
15.3.3 Route of Administration
15.3.4 Orphan Drug/Fast Track/Special Designation
15.3.5 Geography
15.3.6 Type of Molecular Entity
15.3.7 Current Status
15.4 Drug Overview
15.5 Drug Mechanism of Action
15.6 Clinical/Pre-clinical Trial Details
15.7 Latest Drug Developments
16 Protekt Therapeutics Ltd Mild Cognitive Impairment (MCI) Pipeline Details
16.1 Protekt Therapeutics Ltd Business Profile
16.2 Protekt Therapeutics Ltd Mild Cognitive Impairment (MCI) Drug Details
16.3 Drug Snapshot
16.3.1 Originator
16.3.2 Collaborator/Co-Developer
16.3.3 Route of Administration
16.3.4 Orphan Drug/Fast Track/Special Designation
16.3.5 Geography
16.3.6 Type of Molecular Entity
16.3.7 Current Status
16.4 Drug Overview
16.5 Drug Mechanism of Action
16.6 Clinical/Pre-clinical Trial Details
16.7 Latest Drug Developments
17 SBI Pharmaceuticals Co Ltd Mild Cognitive Impairment (MCI) Pipeline Details
17.1 SBI Pharmaceuticals Co Ltd Business Profile
17.2 SBI Pharmaceuticals Co Ltd Mild Cognitive Impairment (MCI) Drug Details
17.3 Drug Snapshot
17.3.1 Originator
17.3.2 Collaborator/Co-Developer
17.3.3 Route of Administration
17.3.4 Orphan Drug/Fast Track/Special Designation
17.3.5 Geography
17.3.6 Type of Molecular Entity
17.3.7 Current Status
17.4 Drug Overview
17.5 Drug Mechanism of Action
17.6 Clinical/Pre-clinical Trial Details
17.7 Latest Drug Developments
18 Therapix Biosciences Ltd Mild Cognitive Impairment (MCI) Pipeline Details
18.1 Therapix Biosciences Ltd Business Profile
18.2 Therapix Biosciences Ltd Mild Cognitive Impairment (MCI) Drug Details
18.3 Drug Snapshot
18.3.1 Originator
18.3.2 Collaborator/Co-Developer
18.3.3 Route of Administration
18.3.4 Orphan Drug/Fast Track/Special Designation
18.3.5 Geography
18.3.6 Type of Molecular Entity
18.3.7 Current Status
18.4 Drug Overview
18.5 Drug Mechanism of Action
18.6 Clinical/Pre-clinical Trial Details
18.7 Latest Drug Developments
19. Latest Mild Cognitive Impairment (MCI) Drug Pipeline Developments, 2019
20. Appendix
20.1 About Us
20.2 Sources and Methodology
20.3 Contact Information

Companies Mentioned

  • AbbVie Inc

  • AgeneBio Inc

  • Avraham Pharmaceuticals Ltd

  • Biogen Inc

  • CereSpir Inc

  • Eisai Co Ltd

  • Eli Lilly and Co

  • IntelGenx Corp

  • Neuron Biopharma SA

  • Octapharma AG

  • Partner Therapeutics Inc

  • Pfizer Inc

  • Protekt Therapeutics Ltd

  • SBI Pharmaceuticals Co Ltd

  • Therapix Biosciences Ltd